# Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial - Part 2

> **NCT07227246** · PHASE3 · RECRUITING · sponsor: **Joseph Broderick, MD** · enrollment: 350 (estimated)

## Conditions studied

- Intracerebral Hemorrhage

## Interventions

- **BIOLOGICAL:** Recombinant Factor VIIa
- **BIOLOGICAL:** Biological/Vaccine: Placebo

## Key facts

- **NCT ID:** NCT07227246
- **Lead sponsor:** Joseph Broderick, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-06
- **Primary completion:** 2029-01
- **Final completion:** 2029-06
- **Target enrollment:** 350 (ESTIMATED)
- **Last updated:** 2026-04-22

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07227246

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07227246, "Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial - Part 2". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07227246. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*